BIO-key International (NASDAQ:BKYI) Releases Earnings Results, Misses Expectations By $3.66 EPS

BIO-key International (NASDAQ:BKYI) issued its quarterly earnings results on Friday. The technology company reported ($4.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($3.66), Zacks reports. BIO-key International had a negative return on equity of 67.31% and a negative net margin of 50.01%. The business had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $2.40 million.

Here are the key takeaways from BIO-key International’s conference call:

• Software growth lifted margins: Q3 license-fee revenue rose 39% year over year and reached 86% of total revenue, helping gross margin improve to 90% from 77% and reducing the operating loss 8%. Total revenue nevertheless fell 4%, largely because hardware sales declined.
• International regulated-sector wins expanded the pipeline: BIO-key highlighted new government and financial-services customers, including the Central Bank of Jordan, and said it has added eight Middle East customers in roughly seven months. Management described larger opportunities ahead, but timing and collections remain dependent on customer and partner deployments.
• New U.S. opportunities and product initiatives: A casino resort signed a prepaid, three-year PortalGuard agreement, and BIO-key said its FIDO-certified Passkey:YOU product is nearing launch, with agentic-AI authentication as a potential use case. Management sees partner-led sales and additional verticals as growth opportunities, though adoption is not yet established.
• Balance sheet strengthened: The company retired its remaining note debt, ended the quarter with $2.2 million in cash and $3.1 million of working capital, and said it does not currently expect to need additional capital. Management is targeting profitability as it approaches Q1 2027.
• Reported loss per share was sharply affected by a financing-related accounting item: A non-cash $4.5 million deemed dividend tied to an August warrant inducement brought Q3 net loss available to common stockholders to $5.9 million, or $4 per share, despite improvement in the operating loss. Hardware revenue also fell to $12,000 from $364,000 a year earlier, with a large customer order delayed into smaller shipments.

BIO-key International Price Performance

BKYI traded down $0.46 during trading on Friday, reaching $2.12. 215,683 shares of the company’s stock were exchanged, compared to its average volume of 1,709,848. BIO-key International has a 1 year low of $1.55 and a 1 year high of $10.70. The stock has a market capitalization of $4.32 million, a P/E ratio of -0.52 and a beta of 0.52. The company’s fifty day simple moving average is $2.47 and its 200-day simple moving average is $4.41.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Wall Street Zen upgraded BIO-key International to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of BIO-key International in a research note on Thursday, October 15th. Finally, Zacks Research upgraded BIO-key International to a “hold” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce”.

About BIO-key International

BIO-key International, Inc. (NASDAQ: BKYI) develops biometric authentication and identity and access management solutions. The company helps organizations secure access to applications, networks, devices and data through fingerprint recognition and other authentication methods designed to reduce reliance on passwords. Its product portfolio includes PortalGuard, an identity and access management platform that supports single sign-on, multifactor authentication, self-service password management and access control.